## Clarissa S Gama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8251631/publications.pdf

Version: 2024-02-01

113	6,061	38	75
papers	citations	h-index	g-index
115	115	115	6633
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews, 2011, 35, 804-817.	6.1	1,007
2	Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 2011, 45, 995-1004.	3.1	349
3	Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research, 2011, 45, 156-161.	3.1	208
4	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1677-1681.	4.8	188
5	Staging systems in bipolar disorder: an <scp>I</scp> nternational <scp>S</scp> ociety for <scp>B</scp> ipolar <scp>D</scp> isorders <scp>T</scp> ask <scp>F</scp> orce <scp>R</scp> eport. Acta Psychiatrica Scandinavica, 2014, 130, 354-363.	4.5	175
6	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders, 2011, 135, 389-394.	4.1	162
7	Increased serum S100B protein in schizophrenia: a study in medication-free patients. Journal of Psychiatric Research, 2001, 35, 11-14.	3.1	137
8	Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters, 2007, 420, 45-48.	2.1	135
9	Similarities in serum oxidative stress markers and inflammatory cytokines inÂpatients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research, 2012, 46, 819-824.	3.1	130
10	Clinical Staging in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, e450-e456.	2.2	125
11	Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine. Schizophrenia Research, 2013, 151, 12-19.	2.0	112
12	Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. Journal of Psychiatric Research, 2009, 43, 1200-1204.	3.1	111
13	Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia. Journal of Clinical Psychiatry, 2009, 70, 1416-1423.	2.2	108
14	A systemic toxicity index developed to assess peripheral changes in mood episodes. Molecular Psychiatry, 2010, 15, 784-786.	7.9	105
15	Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	1.7	102
16	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 512-515.	4.8	101
17	Staging and Neuroprogression in Bipolar Disorder: A Systematic Review of the Literature. Revista Brasileira De Psiquiatria, 2013, 35, 70-74.	1.7	97
18	Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. Journal of Psychiatric Research, 2013, 47, 1396-1402.	3.1	92

#	Article	IF	Citations
19	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. Journal of Psychiatric Research, 2013, 47, 1376-1382.	3.1	84
20	Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatrica Scandinavica, 2014, 129, 437-444.	4.5	84
21	Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. Frontiers in Psychiatry, 2018, 9, 241.	2.6	83
22	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 2012, 10, 91.	5.5	81
23	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, 2009, 114, 1-13.	4.1	<b>7</b> 5
24	Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neuroscience Letters, 2009, 453, 195-198.	2.1	72
25	Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience, 2014, 259, 223-231.	2.3	71
26	The association of child abuse and neglect with adult disability in schizophrenia and the prominent role of physical neglect. Child Abuse and Neglect, 2009, 33, 618-624.	2.6	69
27	Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. Schizophrenia Research, 2015, 165, 163-170.	2.0	67
28	Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: Study of sex differences and brain oxidative alterations. Behavioural Brain Research, 2017, 331, 30-37.	2.2	66
29	Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: A study in adolescent rats with ketamine-induced model of schizophrenia. Schizophrenia Research, 2012, 141, 162-167.	2.0	65
30	Mirtazapine addâ€on therapy in the treatment of schizophrenia with atypical antipsychotics: a doubleâ€blind, randomised, placeboâ€controlled clinical trial. Human Psychopharmacology, 2009, 24, 233-238.	1.5	60
31	Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. Neuroscience Letters, 2011, 491, 207-210.	2.1	59
32	Childhood trauma, impulsivity, and executive functioning in crack cocaine users. Comprehensive Psychiatry, 2012, 53, 238-244.	3.1	57
33	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. CNS Spectrums, 2009, 14, 357-360.	1.2	53
34	Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. Journal of Affective Disorders, 2015, 182, 64-69.	4.1	47
35	Volumetric brain magnetic resonance imaging predicts functioning in bipolar disorder: A machine learning approach. Journal of Psychiatric Research, 2018, 103, 237-243.	3.1	47
36	Association of the gene encoding neurogranin with schizophrenia in males. Journal of Psychiatric Research, 2008, 42, 125-133.	3.1	45

#	Article	IF	CITATIONS
37	Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. Journal of Psychiatric Research, 2010, 44, 561-565.	3.1	44
38	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. Revista Brasileira De Psiquiatria, 2016, 38, 281-286.	1.7	43
39	Brainâ€derived neurotrophic factor and inflammatory markers in schoolâ€aged children with early trauma. Acta Psychiatrica Scandinavica, 2015, 131, 360-368.	<b>4.</b> 5	41
40	G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics, 2008, 9, 1429-1436.	1.3	39
41	Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics. Pharmacogenetics and Genomics, 2008, 18, 599-609.	1.5	38
42	Obesity is associated with previous suicide attempts in bipolar disorder. Acta Neuropsychiatrica, 2010, 22, 63-67.	2.1	38
43	Association of biomarkers and depressive symptoms in schizophrenia. Neuroscience Letters, 2011, 505, 282-285.	2.1	38
44	Telomere length in subjects with schizophrenia, their unaffected siblings and healthy controls: Evidence of accelerated aging. Schizophrenia Research, 2016, 174, 39-42.	2.0	38
45	Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neuroscience Letters, 2011, 502, 143-146.	2.1	37
46	The Relationship of Intellectual Functioning and Cognitive Performance to Brain Structure in Schizophrenia. Schizophrenia Bulletin, 2017, 43, sbw090.	4.3	37
47	Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. Journal of Psychiatric Research, 2010, 44, 1158-1162.	3.1	35
48	Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging. Schizophrenia Bulletin, 2018, 44, 158-167.	4.3	35
49	Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neuroscience Letters, 2008, 433, 270-273.	2.1	34
50	Carnosic Acid Protects Mitochondria of Human Neuroblastoma SH-SY5Y Cells Exposed to Paraquat Through Activation of the Nrf2/HO-1Axis. Molecular Neurobiology, 2017, 54, 5961-5972.	4.0	33
51	Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1595-1598.	4.8	32
52	Verbal episodic memory along the course of schizophrenia and bipolar disorder: A new perspective. European Neuropsychopharmacology, 2015, 25, 169-175.	0.7	31
53	Molecular diversity at the <i>CYP2D6</i> locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics, 2009, 10, 1457-1466.	1.3	30
54	Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. Journal of Psychopharmacology, 2009, 23, 985-987.	4.0	30

#	Article	IF	CITATIONS
55	Pinocembrin Provides Mitochondrial Protection by the Activation of the Erk1/2-Nrf2 Signaling Pathway in SH-SY5Y Neuroblastoma Cells Exposed to Paraquat. Molecular Neurobiology, 2017, 54, 6018-6031.	4.0	30
56	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica, 2009, 21, 272-274.	2.1	29
57	Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Revista Brasileira De Psiquiatria, 2008, 30, 337-340.	1.7	28
58	Neurobiological underpinnings of bipolar disorder focusing on findings of diffusion tensor imaging: a systematic review. Revista Brasileira De Psiquiatria, 2016, 38, 167-175.	1.7	28
59	Anxiolytic properties of N -acetylcysteine in mice. Behavioural Brain Research, 2017, 317, 461-469.	2.2	26
60	Sex influences in the preventive effects of N-acetylcysteine in a two-hit animal model of schizophrenia. Journal of Psychopharmacology, 2020, 34, 125-136.	4.0	26
61	Oxidative stress may be a common mechanism linking major depression and osteoporosis. Acta Neuropsychiatrica, 2008, 20, 112-116.	2.1	23
62	Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. Neuroscience Letters, 2008, 440, 197-201.	2.1	22
63	Symptom Dimensional Approach and BDNF in Unmedicated Obsessive-Compulsive Patients: <i>An Exploratory Study</i> . CNS Spectrums, 2011, 16, 179-189.	1.2	22
64	Cognition and functioning in bipolar depression. Revista Brasileira De Psiquiatria, 2016, 38, 201-206.	1.7	22
65	Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia. Life Sciences, 2015, 121, 65-69.	4.3	21
66	Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry. World Journal of Biological Psychiatry, 2019, 20, 310-319.	2.6	21
67	The effect of sunlight exposure on interleukin-6 levels in depressive and non-depressive subjects. BMC Psychiatry, 2013, 13, 75.	2.6	20
68	Differences in eotaxin serum levels patients with recent onset and in chronic stable schizophrenia: A clue for understanding accelerating aging profile. Schizophrenia Research, 2014, 152, 528-529.	2.0	19
69	Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. Revista Brasileira De Psiquiatria, 2015, 37, 121-125.	1.7	19
70	$\hat{l}_{\pm}$ -Lipoic Acid as Adjunctive Treatment for Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 697-701.	1.4	19
71	Accumbens volumes are reduced among crack-cocaine users. Neuroscience Letters, 2017, 645, 86-89.	2.1	18
72	Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder. Journal of Psychiatric Research, 2013, 47, 1546-1548.	3.1	16

#	Article	IF	Citations
73	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. Psychiatry Research - Neuroimaging, 2015, 234, 84-89.	1.8	16
74	Mediator effects of parameters of inflammation and neurogenesis from a $\langle i \rangle N \langle i \rangle$ -acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	2.1	16
75	Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls. Psychiatry Research, 2012, 200, 1018-1021.	3.3	15
76	Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1475-1486.	0.8	14
77	Perceived childhood adversities: Impact of childhood trauma to estimated intellectual functioning of individuals with bipolar disorder. Psychiatry Research, 2019, 274, 345-351.	3.3	14
78	N-3 polyunsaturated fatty acids and clozapine abrogates poly I: C-induced immune alterations in primary hippocampal neurons. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 186-196.	4.8	14
79	Imaging Social and Environmental Factors as Modulators of Brain Dysfunction: Time to Focus on Developing Non-Western Societies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 8-15.	1.5	14
80	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. Acta Neuropsychiatrica, 2009, 21, 285-291.	2.1	13
81	Verbal memory impairment in healthy siblings of patients with schizophrenia. Schizophrenia Research, 2013, 150, 580-582.	2.0	13
82	Improvement of schizophrenia with electroconvulsive therapy and serum brainâ€derived neurotrophic factor levels: Lack of association in a pilot study. Psychiatry and Clinical Neurosciences, 2010, 64, 663-665.	1.8	11
83	Short-Term Treatment of Catatonia With Amantadine in Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 569-572.	1.4	11
84	Treatment delay is associated with more episodes and more severe illness staging progression in patients with bipolar disorder. Psychiatry Research, 2015, 227, 372-373.	3.3	11
85	Sobrepeso e obesidade em pacientes esquizofrênicos em uso de clozapina comparado com o uso de outros antipsicóticos. Revista De Psiquiatria Do Rio Grande Do Sul, 2006, 28, 120-128.	0.3	10
86	Functioning in early and late stages of schizophrenia. Trends in Psychiatry and Psychotherapy, 2014, 36, 209-213.	0.8	10
87	Family-based and case-control studies reveal no association oflipocalin-type prostaglandin D2 synthase with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 642-646.	1.7	9
88	Effects of <i>N</i> -acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. Acta Neuropsychiatrica, 2009, 21, 239-245.	2.1	9
89	White matter volume is decreased in bipolar disorder at early and late stages. Trends in Psychiatry and Psychotherapy, 2018, 40, 277-284.	0.8	9
90	Resveratrol prevents long-term structural hippocampal alterations and modulates interneuron organization in an animal model of ASD. Brain Research, 2021, 1768, 147593.	2.2	9

#	Article	IF	Citations
91	Lack of Association Between Serum Brain-Derived Neurotrophic Factor Levels and Improvement of Schizophrenia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Trial of Memantine as Adjunctive Therapy to Clozapine. Journal of Clinical Psychiatry, 2010, 71, 91-92.	2.2	9
92	Transthyretin: No association between serum levels or gene variants and schizophrenia. Journal of Psychiatric Research, 2007, 41, 667-672.	3.1	8
93	Mania switch induced by amantadine in bipolar disorder: report of three cases. Revista Brasileira De Psiquiatria, 2010, 32, 467-469.	1.7	8
94	Relato do uso de clozapina em 56 pacientes atendidos pelo Programa de Atenção à Esquizofrenia Refratária da Secretaria da Saúde e do Meio Ambiente do Estado do Rio Grande do Sul. Revista De Psiquiatria Do Rio Grande Do Sul, 2004, 26, 21-28.	0.3	7
95	Elevated serum protein oxidative stress in siblings of patients with schizophrenia. Schizophrenia Research, 2013, 147, 398-399.	2.0	7
96	The Relationship between Cytokines and Verbal Memory in Individuals with Schizophrenia and Their Unaffected Siblings. NeuroImmunoModulation, 2018, 25, 334-339.	1.8	7
97	Cardiovascular risk and bipolar disorder: factors associated with a positive coronary calcium score in patients with bipolar disorder type 1. Revista Brasileira De Psiquiatria, 2018, 40, 163-168.	1.7	7
98	Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models. Revista Brasileira De Psiquiatria, 2022, 44, 74-80.	1.7	7
99	Reduced serum non-enzymatic antioxidant defense and increased lipid peroxidation in schizophrenic patients on a hypocaloric diet. Neuroscience Letters, 2012, 512, 43-47.	2.1	6
100	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Revista Brasileira De Psiquiatria, 2021, , .	1.7	6
101	Right hippocampus size is negatively correlated with leptin serum levels in bipolar disorder. Psychiatry Research, 2015, 230, 719-721.	3.3	5
102	Effects of N-acetylcysteine on amphetamine-induced sensitization in mice. Revista Brasileira De Psiquiatria, 2018, 40, 169-173.	1.7	5
103	Estado nutricional de pacientes com esquizofrenia frequentadores do Centro de Atenção Psicossocial (CAPS) do Hospital de ClÃnicas de Porto Alegre. Jornal Brasileiro De Psiquiatria, 2010, 59, 126-130.	0.7	5
104	BDNF: A biomarker for social vulnerability in individuals diagnosed with gender dysphoria. Journal of Psychiatric Research, 2014, 50, 16-17.	3.1	4
105	Serum concentrations of brain-derived neurotrophic factor in patients diagnosed with gender dysphoria undergoing sex reassignment surgery. Trends in Psychiatry and Psychotherapy, 2017, 39, 43-47.	0.8	4
106	Accelerated aging signatures in subjects with schizophrenia and their unaffected siblings. Journal of Psychiatric Research, 2021, 139, 30-37.	3.1	4
107	Hippocampus size does not correlate with body mass index in bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 86-87.	1.7	4
108	Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study. Revista Brasileira De Psiquiatria, 2006, 28, 339-340.	1.7	4

#	Article	IF	CITATIONS
109	Risk of neutropenia among clozapine users and non-users: results from 5,847 patients. Revista Brasileira De Psiquiatria, 2021, , .	1.7	3
110	Changes in verbal learning of patients with schizophrenia: Results from a randomized, doubleâ€blind, placeboâ€controlled trial of amantadine adjunctive to antipsychotics. Schizophrenia Research, 2015, 168, 571-572.	2.0	2
111	Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series. Revista Brasileira De Psiquiatria, 2010, 32, 193-194.	1.7	2
112	Hypersalivation Associated with Olanzapine and Valproate Combination: A Case Report. CNS Spectrums, 2011, 16, 83-83.	1.2	1
113	Analyzing leukocyte telomere length in bipolar disorder: Authors' reply. Revista Brasileira De Psiquiatria, 2017, 39, 275-276.	1.7	1